Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Olema Oncology (Nasdaq: OLMA) granted inducement stock options to five new employees to purchase an aggregate of 154,700 shares, effective May 1, 2026. The options vest over four years (25% after one year, then monthly over three years), have a 10-year term and an exercise price of $14.32 per share, equal to the last reported sale price on May 1, 2026. Awards were approved by the Compensation Committee and granted under the company’s 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – OLMA
On the day this news was published, OLMA gained 0.07%, reflecting a mild positive market reaction. Argus tracked a peak move of +11.0% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $873K to the company's valuation, bringing the market cap to $1.25B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
OLMA was down 0.62% while key peers showed mixed moves: ARVN appeared in momentum scanners moving up and ORKA moving down. With peers split between gains and losses, the modest dip in OLMA looks more company-specific than part of a broad biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | Board appointment | Positive | +1.9% | Added experienced biopharma executive to board as lead programs advance. |
| Apr 21 | Clinical data plans | Positive | -0.6% | Planned initial OP-3136 data and OPERA-02 poster at ASCO 2026. |
| Apr 17 | Preclinical data | Positive | -1.4% | Reported AACR preclinical data for palazestrant and OP-3136 combinations. |
| Apr 02 | Inducement grants | Neutral | +0.7% | Announced stock option inducement grants to new employees under 2022 plan. |
| Mar 17 | AACR preview | Positive | -3.3% | Outlined upcoming AACR preclinical posters on palazestrant and OP-3136. |
Recent news has been largely positive or developmental (clinical data, preclinical posters, governance, inducement grants) with mixed price reactions: some positive moves on management and option news, but pullbacks around clinical and preclinical updates.
Over the past several weeks, OLMA has issued a series of updates spanning management changes, clinical milestones, and employee equity incentives. On Apr 29, a new director joined the board as Phase 3 programs advance, and on Apr 21 and Apr 17 the company highlighted clinical and preclinical data for palazestrant and OP-3136. A prior inducement grant announcement on Apr 2 drew a small positive move. Today’s option grants under the 2022 Inducement Plan fit into this ongoing pattern of governance and R&D-driven developments.
Market Pulse Summary
This announcement details routine equity compensation: OLMA granted stock options on 154,700 shares to five new employees at an exercise price of $14.32, vesting over four years with a 10-year term. It follows a similar inducement grant disclosed on Apr 2, 2026. In the broader context of ongoing Phase 3 and preclinical programs, investors may focus on how such grants support talent retention while modestly increasing potential future share issuance.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
stock options financial
AI-generated analysis. Not financial advice.
SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to five new employees to purchase an aggregate of 154,700 shares of the Company's common stock, effective as of May 1, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
